| Literature DB >> 31737563 |
Zhen Yuan1, Dongyan Cao1, Jie Yang1, Mei Yu1, Keng Shen1, Jiaxin Yang1, Ying Zhang1, Huimei Zhou1.
Abstract
Study Objective: To compare the surgical and oncologic outcomes between open abdomen radical hysterectomy (ARH) and laparoscopic radical hysterectomy (LRH) for cervical cancer.Entities:
Keywords: cervical cancer; laparoscopy; oncologic outcomes; open abdominal surgery; surgical outcomes
Year: 2019 PMID: 31737563 PMCID: PMC6833183 DOI: 10.3389/fonc.2019.01107
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1The flow of patients included in this study.
Baseline clinical characteristics of the patients. Data are presented as number (%), mean (±SD) or median (25th percentiles- 75th percentiles).
| Age (years) | 44.56 ± 7.60 | 43.58 ± 8.86 | 0.405 |
| BMI (kg/m2) | 24.56 ± 1.50 | 24.36 ± 2.41 | 0.479 |
| Previous abdominal surgery, | 37 (37.4%) | 40 (40.4%) | |
| SCCAg (ng/mL) | 1.20 | 1.20 | 0.549 |
| CA125 (U/ml) | 22.10 | 16.50 | 0.586 |
| Squamous cell cancer, | 82 (82.8%) | 82 (82.8%) | 1.000 |
| Adenocarcinoma, | 13 (13.1%) | 14 (14.1%) | 1.000 |
| Adenosquamous cancer, | 4 (4.1%) | 3 (3.1%) | 1.000 |
| IA2-IB1, | 72 (72.7%) | 73 (73.7%) | 1.000 |
| IB2-IIA2, | 27 (27.3%) | 26 (26.3%) | 1.000 |
| Tumor size | 3.00 | 2.50 | 0.704 |
| Patients with tumor size > 2 cm, | 53 (53.5%) | 50 (50.5%) | 0.776 |
SD, standard deviation; BMI, body mass index; SCCAg, squamous cell carcinoma antigen; CA125, serum cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics.
Pathological high-risk and intermediate-risk factors.
| Pelvic lymph node metastasis, | 10 (10.1%) | 11 (11.1%) | 1.000 |
| Parametrium invasion, | 2 (2.0%) | 0 (0.0%) | 0.497 |
| Vaginal cuff invasion, | 3 (3.0%) | 1 (1.0%) | 0.621 |
| Deep myometrial invasion, | 43 (43.4%) | 37 (37.4%) | 0.469 |
| Lymphovascular space invasion, | 34 (34.3%) | 23 (23.2%) | 0.116 |
| Neoadjuvant chemotherapy, | 20 (20.2%) | 20 (20.2%) | 1.000 |
| TP | 17 (85.0%) | 16 (80.0%) | >0.999 |
| Others | 3 (15.0%) | 4 (20.0%) | >0.999 |
| Adjuvant chemotherapy, | 22 (22.2%) | 21 (21.2%) | 1.000 |
| TP | 18 (81.8%) | 19 (90.5%) | 0.705 |
| Others | 4 (18.2%) | 2 (9.5%) | 0.705 |
| Adjuvant radiation, | 64 (64.6%) | 50 (50.5%) | 0.061 |
| Concurrent DDP-based chemotherapy | 40 (62.5%) | 27 (54.0%) | 0.470 |
| Others | 24 (37.5%) | 23 (46.0%) | 0.470 |
TP, paclitaxel and cisplatin; DDP, cisplatin.
Surgery-related and oncological outcomes of the patients.
| Operating time (min) | 165 | 180 | 0.377 |
| The number of resected lymph nodes | 27 | 26 | 0.850 |
| Blood loss (ml) | 400.00 | 200.00 | <0.001 |
| Transfusion, | 20 (20.2%) | 1 (1.0%) | <0.001 |
| Severe complications in 30 postoperative days, | 19 (19.2%) | 22 (22.2%) | 0.726 |
| Severe complications after 30 postoperative days, | 2 (2.0%) | 5 (5.1%) | 0.445 |
| Unexpected second surgery, | 3 (3.0%) | 4 (4.0%) | 1.000 |
| Unexpected second hospitalization, | 2 (2.0%) | 5 (5.1%) | 0.445 |
| Postoperative first aerofluxus time (days) | 3.00 | 2.00 | <0.001 |
| Length of hospital stay(days) | 11.00 | 10.00 | 0.224 |
| Postoperative first uterine catheter removal time (days) | 14.00 | 14.00 | 0.189 |
| Urine retention, | 8 (8.1%) | 22 (22.2%) | 0.009 |
| Relapse, | 4 (4.0%) | 8 (8.1%) | 0.375 |
| Pelvic cavity | 2 (50.0%) | 5 (62.5%) | >0.999 |
| Distance | 2 (50.0%) | 3 (37.5%) | >0.999 |
| Mortality, | 3 (3.0%) | 4 (4.0%) | 1.000 |
| Follow-up time (months) | 69.00 | 59.00 | |
Figure 2Surgery-related outcomes. (A) Blood loss. (B) Transfusion rate (C) Resected parametrium breadth. (D) Aerofluxus time. (E) Urinary retention rate. **P < 0.01.
The detail information of surgery-related complications in two groups.
| Severe complications in 30 postoperative days, | 19 | 22 |
| Vesicovaginal fistula | 0 | 2 |
| Ureteral fistula | 1 | 1 |
| Intestinal obstruction | 5 | 0 |
| Poor wound healing | 6 | 1 |
| Pelvic lymphocyst (Puncture needed) | 1 | 1 |
| Fever/Infection | 6 | 15 |
| Deep vein thrombosis | 0 | 1 |
| Rectovaginal fistula | 0 | 1 |
| Severe complications after 30 postoperative days, | 2 | 5 |
| Hydronephrosis (Double J needed) | 2 | 4 |
| Urinary incontinence | 0 | 1 |
Figure 3The curve of Disease-free survival (DFS) and overall survival (OS). (A) The curve of DFS. (B) The curve of OS.
Figure 4The evolved expertise in laparoscopic radical hysterectomy. (A) Uterine hitch technique replacing uterine manipulator. (B) Vaginal cerclage before creating an incision in the vaginal wall.